Fluidigm Corp. is buying DVS Sciences Inc. for $208 million.
CVS develops single-cell protein analysis systems, which are used in biological research.
Fliudigm develops, manufactures and markets microfluidic systems to academic institutions, laboratories and pharmaceutical companies, and are used for research. The company will pay the $208 million price tag through a combination of common stock and cash. The deal is expected to close in February.
The combined companies will be able to offer a portfolio of technologies that service the single-cell genomics and protein-studying markets.
Piper Jaffray & Co. is acting as Fluidigm’s financial adviser, while Wilson Sonsini Goodrich & Rosati PC is acting as legal counsel. Jefferies LLC is DVS’ financial adviser, and Latham & Watkins LLP is providing legal advice.
The deal comes on the same day that GVK Biosciences bought Aragen Bioscience in another medical research transaction.